Biogen: Alzheimer Disease trials

The registry lists 13 Alzheimer Disease studies with Biogen as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 5Phase 2 2Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseTerminatedNCT05310071Phase 3Results posted
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205TerminatedNCT04241068Phase 3Results posted
• A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormalitiesTerminatedNCT03639987Phase 2Results posted
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseTerminatedNCT03352557Phase 2Results posted
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedNCT02484547Phase 3Results posted
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseTerminatedNCT02477800Phase 3Results posted
• An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the USTerminatedNCT05097131
• Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)CompletedNCT03088956
• Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's DiseaseCompletedNCT03056729Phase 1
• Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy ParticipantsCompletedNCT02782975Phase 1
• Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's DiseaseCompletedNCT02434718Phase 1
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's DiseaseTerminatedNCT01677572Phase 1
• Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's DiseaseCompletedNCT01397539Phase 1